Metagenomi (MGX) to Release Earnings on Wednesday

Key Points

• Metagenomi will report Q4 2025 results before the market opens on Wednesday, April 1, with analysts expecting about -$0.6059 EPS and $7.327M revenue.
• In the prior quarter the company missed estimates (reported -$0.60 EPS vs. -$0.58 consensus) and revenue of $3.91M fell well short of expectations, and analysts project roughly -$2 EPS this fiscal year and -$3 EPS next year.
• Shares trade near $1.37 with a market cap of ~$51.5M; despite a consensus price target of $10 and an average "Moderate Buy" rating, analyst opinions are mixed while institutional investors (e.g., Renaissance, Jane Street, Two Sigma) have recently increased positions.

Metagenomi (NASDAQ:MGX - Get Free Report) is expected to be issuing its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.6059) per share and revenue of $7.3270 million for the quarter. Investors are encouraged to explore the company's upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 5, 2026 at 3:00 PM ET.

Metagenomi (NASDAQ:MGX - Get Free Report) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.02). Metagenomi had a negative return on equity of 47.14% and a negative net margin of 348.54%.The firm had revenue of $3.91 million for the quarter, compared to analysts' expectations of $7.33 million. On average, analysts expect Metagenomi to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Metagenomi Stock Performance

NASDAQ MGX opened at $1.37 on Wednesday. The business has a fifty day moving average price of $1.54 and a 200 day moving average price of $1.90. The company has a market cap of $51.54 million, a P/E ratio of -0.58 and a beta of 0.45. Metagenomi has a one year low of $1.23 and a one year high of $3.95.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Metagenomi from a "hold" rating to a "sell" rating in a report on Saturday. Weiss Ratings restated a "sell (d-)" rating on shares of Metagenomi in a research report on Monday, December 22nd. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $10.00.

Institutional Trading of Metagenomi

Several large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC raised its holdings in shares of Metagenomi by 276.3% during the 4th quarter. Renaissance Technologies LLC now owns 628,400 shares of the company's stock worth $1,018,000 after acquiring an additional 461,400 shares during the period. Jane Street Group LLC grew its holdings in shares of Metagenomi by 341.6% in the fourth quarter. Jane Street Group LLC now owns 433,859 shares of the company's stock valued at $703,000 after purchasing an additional 335,604 shares during the period. Norges Bank purchased a new stake in shares of Metagenomi in the second quarter valued at about $373,000. Bridgeway Capital Management LLC increased its position in Metagenomi by 102.1% during the fourth quarter. Bridgeway Capital Management LLC now owns 395,800 shares of the company's stock worth $641,000 after purchasing an additional 200,000 shares during the last quarter. Finally, Two Sigma Investments LP increased its position in Metagenomi by 1,394.4% during the third quarter. Two Sigma Investments LP now owns 207,528 shares of the company's stock worth $492,000 after purchasing an additional 193,641 shares during the last quarter.

About Metagenomi

Metagenomi, Inc NASDAQ: MGX is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company's proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi's technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.